Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 108,238	$ 160,203
Short-term investments	73,371	7,133
Accounts receivable	5,532	12,634
Note receivable	5,547	0
Inventory	802	269
Capitalized expenses (Viking IPO)	0	2,268
Current debt issuance costs	834	809
Restricted investments	600	1,261
Other current assets	1,801	1,842
Total current assets	196,725	186,419
Property and equipment, net	405	486
Investment in Viking Therapeutics	33,996	0
Intangible assets, net	49,535	50,723
Goodwill	12,238	12,238
Commercial license rights	8,598	4,568
Long-term debt issuance costs	2,964	3,388
Other assets	301	207
Total assets	304,762	258,029
Current liabilities:
Accounts payable (including $0 and $2,211 related to a VIE, respectively)	2,708	7,698
Accrued liabilities	5,629	4,866
Current contingent liabilities	7,674	6,796
Current lease exit obligations	1,638	2,356
Other current liabilities	300	1,063
Total current liabilities	17,949	22,779
Long-term deferred revenue, net	2,083	2,085
Long-term lease exit obligations	228	934
Deferred income taxes	3,059	2,792
Long-term contingent liabilities	11,089	8,353
Long-term debt, net	200,567	195,908
Other long-term liabilities	734	770
Total liabilities	$ 235,709	$ 233,621
Commitments and Contingencies
Stockholders' equity:
Common stock, $0.001 par value; 33,333,333 shares authorized; 19,837,109 and 19,575,150 shares issued and outstanding at June 30, 2015 and December 31, 2014, respectively	$ 20	$ 20
Additional paid-in capital	692,765	680,660
Accumulated other comprehensive income	11,265	4,953
Accumulated deficit	(634,997)	(659,315)
Total stockholders' equity attributable to Ligand Pharmaceuticals	69,053	26,318
Noncontrolling interests	0	(1,910)
Total liabilities and stockholders' equity	$ 304,762	$ 258,029